Benefits
Selective increase in beneficial bifidobacteria
Bimuno® has consistently increased fecal bifidobacteria counts across multiple human RCTs in healthy adults, older adults, and IBS sufferers. Selectively raising bifidobacteria is associated with improved short-chain fatty acid production and supports a healthier baseline gut microbial environment.
Support for IBS symptom relief
Randomized trials in adults with IBS have shown improvements in stool consistency, flatulence, bloating, and overall symptom scores with B-GOS supplementation over several weeks. Quality of life and anxiety scores also improved in some trials, particularly at higher dose levels.
May reduce traveller's diarrhea incidence and severity
Pre-travel supplementation with Bimuno® has been associated with reduced incidence and severity of traveller's diarrhea in randomized human studies, with improvements also reported in associated abdominal pain and quality-of-life scores during travel to higher-risk regions.
Immune function support in older adults
In healthy elderly volunteers, B-GOS supplementation has been associated with improved markers of immune function alongside the expected bifidogenic effect, including modulation of NK cell activity and inflammatory cytokine profiles — relevant to age-associated immunosenescence.
Modulation of cortisol awakening response
B-GOS has been studied for gut–brain axis effects, with one well-known trial reporting a reduction in the salivary cortisol awakening response and a shift in emotional processing toward positive information after three weeks of supplementation. Effects are modest but consistent with broader prebiotic–HPA-axis literature.
Mechanism of action
Bifidogenic selectivity through specific glycosidic linkages
Because Bimuno® is produced using a Bifidobacterium-derived β-galactosidase, the resulting GOS mixture contains specific linkages that are preferentially fermented by intestinal bifidobacteria. This selectivity helps shift the colonic microbial profile toward a more bifidogenic state over weeks of supplementation.
Short-chain fatty acid production
Fermentation of B-GOS in the colon increases short-chain fatty acids (acetate, propionate, butyrate). Butyrate is a primary energy substrate for colonocytes and supports intestinal barrier integrity, while propionate and acetate influence appetite signaling and hepatic metabolism.
Modulation of intestinal immune function
The microbiota shift triggered by B-GOS interacts with gut-associated lymphoid tissue, modulating cytokine secretion, regulatory T-cell signaling, and pattern-recognition receptor activity. These changes may underlie observed effects on NK activity, traveller's diarrhea, and inflammatory tone in the elderly.
Gut–brain axis signalling
Prebiotic-induced changes in microbiota composition may signal to the brain via vagal afferents, microbial metabolites, and HPA-axis modulation. This pathway is implicated in the observed reductions in cortisol awakening response and shifts in emotional processing in healthy adults.
Clinical trials
Randomized, double-blind, placebo-controlled trial of trans-galactooligosaccharide prebiotic (3.5 g/day, 7 g/day, or 7 g/day placebo) in 44 IBS patients over 12 weeks. Outcomes: fecal bifidobacteria, stool consistency, flatulence, bloating, symptom severity, anxiety, quality of life. Published in Alimentary Pharmacology & Therapeutics.
44 adults with IBS; 12-week intervention.
B-GOS significantly increased fecal bifidobacteria at both doses. The 3.5 g/day dose improved stool consistency, flatulence, bloating, and overall symptom scores. The 7 g/day dose enhanced quality of life and reduced anxiety. Placebo produced no clinical effects, supporting B-GOS as an effective prebiotic intervention in IBS.
Randomized, double-blind, placebo-controlled crossover trial of B-GOS mixture in healthy elderly volunteers over 10 weeks. Outcomes: fecal microflora profile, NK cell activity, immune markers. Published in American Journal of Clinical Nutrition.
Healthy elderly volunteers; 10-week crossover.
B-GOS significantly modulated the fecal microflora profile (notably increasing bifidobacteria) and improved several immune markers, including markers of phagocytosis and NK cell activity, supporting its potential utility for age-associated immunosenescence.
Three-week, double-blind, placebo-controlled trial of B-GOS (5.5 g/day) versus fructo-oligosaccharides and placebo in healthy adult volunteers. Outcomes: salivary cortisol awakening response, emotional processing tasks. Published in Psychopharmacology (Berlin).
Healthy adults; 3-week trial.
B-GOS supplementation significantly lowered the waking cortisol response compared with placebo and shifted emotional processing toward positive over negative information, suggesting a measurable gut-brain axis effect that may underpin observed stress and mood benefits.